NCT07458906 2026-03-09
DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
The First Affiliated Hospital of Xiamen University
Phase NA Recruiting
Clinical Trials
14 trialsNCT06937905 2026-02-11
TARLANEC
Intergroupe Francophone de Cancerologie Thoracique
Phase 3 Recruiting
NCT06889493 2025-12-17
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
University of Miami
Phase 1 Recruiting
NCT06333314 2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2 Recruiting
NCT04325425 2025-09-30
FOLFIRINEC
Centre Hospitalier Universitaire Dijon
Phase 2 Recruiting
NCT06893783 2025-09-08
DeLLight
Asan Medical Center
Phase 2 Recruiting
NCT06683846 2025-08-24
Ivonescimab in the Treatment of Multiple Advanced Tumors
Fudan University
Phase 2 Recruiting
NCT01876771 2025-08-08
A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT04268121 2025-07-23
NEONEC
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Recruiting
NCT04464122 2025-04-03
REBORN
University of Roma La Sapienza
Recruiting
NCT06242119 2025-02-19
JPET2Clinic
Jagiellonian University
Recruiting
NCT06400654 2024-05-06
NIRVANA
European Institute of Oncology
Recruiting
NCT06369181 2024-04-23
Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
Fudan University
Recruiting
NCT06337760 2024-03-29
YOUNGSTER
European Institute of Oncology
Recruiting